Loading organizations...
§ Venture Capital · Palo Alto, CA, USA
Biopharmaceutical company developing TransCon prodrug therapies for rare diseases, focused on endocrinology and oncology.
Ascendis Pharma is a publicly traded biopharmaceutical company based in Hellerup, Denmark, that develops long-acting prodrug therapies for rare endocrine and oncological diseases using its proprietary TransCon technology platform. The enterprise currently operates with a global workforce of over 800 employees and maintains a market capitalization of approximately $10.4 billion as of mid-2025. Prior to its $108 million initial public offering on the NASDAQ exchange in 2015, the firm secured $109 million in venture capital funding to advance its clinical pipeline and commercialize approved treatments like SKYTROFA and Yorvipath. Ascendis Pharma has received significant financial backing from prominent institutional investors and early-stage venture capital firms, including NEA, Sofinnova Partners, Baker Bros. Advisors, and RA Capital Management. The organization was originally founded in December 2007 by Jørgen Søberg, Jan Møller Mikkelsen, and Torben Stavngaard.
Ascendis Pharma has raised $60.0M across 1 funding round.
Key people at Ascendis Pharma.
Ascendis Pharma was founded in 2007 by Jan Møller Mikkelsen (Co-Founder, President and CEO).
Ascendis Pharma has raised $60.0M in total across 1 funding round.
Ascendis Pharma has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series D in December 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2014 | $60M Series D | Jonathan Silverstein, James Healy, Albert CHA | Janus Henderson Investors, RA Capital Management, Rock Springs Capital, Sectoral Asset Management, Sofinnova Partners, Venrock | Announced |
Ascendis Pharma was founded in 2007 by Jan Møller Mikkelsen (Co-Founder, President and CEO).
Ascendis Pharma has raised $60.0M in total across 1 funding round.
Ascendis Pharma's investors include Jonathan Silverstein, James Healy, Albert Cha, Janus Henderson Investors, RA Capital Management, Rock Springs Capital, Sectoral Asset Management, Sofinnova Partners, Venrock.
Key people at Ascendis Pharma.
